stockrow
Saturday 7 November 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million.
- EPS
- +99.9%
- Free cash flow
- +80.2%
Quarter to June 2026, against a year earlier
0.16
0.01
+6.67%
Follow KALA
Alert me
KALA BIO, Inc. (KALA) P/E ratio
KALA BIO, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 223× (July 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 223×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| KALA KALA BIO, Inc. | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)